Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. Skoulidis F, et al. Among authors: heymach jv. Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17. Cancer Discov. 2018. PMID: 29773717 Free PMC article. Clinical Trial.
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Lynch TJ, et al. Among authors: heymach jv. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4365s-4371s. doi: 10.1158/1078-0432.CCR-06-1005. Clin Cancer Res. 2006. PMID: 16857812 No abstract available.
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. Among authors: heymach jv. J Clin Invest. 2006 Oct;116(10):2695-706. doi: 10.1172/JCI28656. Epub 2006 Aug 10. J Clin Invest. 2006. PMID: 16906227 Free PMC article.
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Lynch TJ, et al. Among authors: heymach jv. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8. doi: 10.1158/1078-0432.CCR-07-0716. Clin Cancer Res. 2007. PMID: 17671145
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. Engelman JA, et al. Among authors: heymach jv. Cancer Res. 2007 Dec 15;67(24):11924-32. doi: 10.1158/0008-5472.CAN-07-1885. Cancer Res. 2007. PMID: 18089823
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Lynch TJ Jr, et al. Among authors: heymach jv. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12. doi: 10.1097/JTO.0b013e318174e9d3. J Thorac Oncol. 2008. PMID: 18520291 Free article.
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Naumov GN, et al. Among authors: heymach jv. Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447865 Free PMC article.
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Byers LA, et al. Among authors: heymach jv. Clin Cancer Res. 2009 Nov 15;15(22):6852-61. doi: 10.1158/1078-0432.CCR-09-0767. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861436 Free PMC article.
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Hanrahan EO, et al. Among authors: heymach jv. J Clin Oncol. 2010 Jan 10;28(2):193-201. doi: 10.1200/JCO.2009.22.4279. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949019 Free PMC article. Clinical Trial.
503 results